Tempus AI announced the launch of its Fuses program, a strategic initiative designed to harness Tempus’ proprietary dataset to generate valuable insights for both patient care and research. This program combines the power of its data and machine learning capabilities to develop an AI-enabled diagnostic platform.
Over the past decade, Tempus has built a multimodal data library comprising over 40 million research records, including more than 1.5 million records with matched clinical data linked with genomic information, 2 million records with imaging data, and approximately 300,000 records with genomic and whole transcriptomic data. This scale is expected to enable groundbreaking discoveries.
Fuses will accelerate Tempus’ comprehensive testing portfolio, expanding its suite of AI-enabled diagnostics. Insights from Fuses will be developed into clinically validated algorithmic diagnostics to enable highly personalized care, such as identifying patients unlikely to respond to approved therapies or those at risk of severe treatment-related events, building on the success of its Immune Profile Score (IPS) launch.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.